Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Study ID
NCT06481228
Status
Recruiting
Apply to this trial

Conditions

  • Acute Lymphoblastic Leukemia, Adult
  • Philadelphia Positive Acute Lymphoblastic Leukemia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CAR-T cells — COMBINATION_PRODUCT
    CAR-T cells as consolidation therapy
  • Venetoclax — DRUG
    BCL2 inhibitor
  • Olverembatinib — DRUG
    TKI

Study Details

In recent years, immunotherapy (eg. blinatumomab, inotuzumab ozogamicin, CAR-T cells) has demonstrated a high safety and efficacy profile in relapsed/refractory (R/R）B-ALL. The available data suggest that the advancement of immunotherapy from R/R field to the frontline setting may be an important approach to increase the depth of remission, which ultimately translates into a survival benefit. In this study, the investigators propose a treatment regimen using CAR-T cell therapy as a consolidation method for Ph+ ALL patients achieving complete remission (CR) with overembatinib, venetoclax and reduced-intensity chemotherapy, aiming to reduce the total cycles of chemotherapy and related toxicities, shorten length of hospitalization, and ultimately improve patients' survival and quality of life.The study endpoints include 2-year disease-free survival (DFS) rate, overall survival (OS) rate, event-free survival (EFS) rate, cumulative molecular remission rate, immune repertoire-minimal residual disease (MRD) remission rate, cumulative relapse rate, treatment-related toxicities, and quality of life. Additionally, an interim analysis will be conducted, with the 1-year DFS rate as the key index for this analysis.

Key Dates

Start date
Jun 4, 2024
Status verified
Feb 2026
Primary completion
Jun 1, 2026
Completion
Jun 1, 2028

Study Design

Enrollment
82 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: TKI Combined With Chemotherapy and Sequential CAR-T Cells
    Ph+ALL patients receiving CAR-T cells as consolidation therapy after achieving complete remission (CR) with overembatinib, venetoclax and reduced-intensity chemotherapy.

Primary Outcome Measure

Disease-free Survival (DFS) [ Time Frame: Up to 2 years post-registration ]

Central Contacts

Related Studies